Burjeel Holdings has long been at the forefront of innovative research and treatment for thalassemia. Since its establishment in 2023, CR-RBD has produced 38 practice-changing publications in top-tier medical journals including Blood and Lancet Haematology, and 23 abstracts with some featured as Plenary presentations during leading international congresses in the US and Europe like American Society of Hematology (ASH) and European Hematology Association (EHA). These publications, some that have been recognized as most accessed globally, uncovered the role of several modifiable risk factors in increasing morbidity and mortality in thalassemia. Meanwhile, the Center has also played a pivotal role in developing innovative therapies to address the uncovered unmet needs by contributing to the groundbreaking ENERGIZE and ENERGIZE-T phase 3, FDA-registration trials run at BMC. Results announced last year demonstrated the efficacy of a new drug called mitapivat, in alleviating anemia and transfusion burden across the range of subtypes of thalassemia. Being a part of this global launch showcases Burjeel’s commitment to advancing healthcare and offering state-of-the-art treatment options to thalassemia patients in the UAE and globally.
Feat Focus Burjeel Holdings 27
Research & Publications
Made with FlippingBook - professional solution for displaying marketing and sales documents online